Harbin Jixianglong Biotech Co., Ltd.
Has Harbin Jixianglong Biotech Co., Ltd. received an FDA warning letter? Yes. FDA issued a warning letter dated May 1, 2026 concerning products containing semaglutide and tirzepatide.
Letter facts
- Letter date
- May 1, 2026 (2026-05-01)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Manufacturer / API
- Products named
- peptide APIssemaglutide APItirzepatide APIGLP-1 receptor agonist APIs
- Violation categories
- MisbrandingCGMP / insanitary conditions
Understanding these violation categories
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
Factual Violation Summary
FDA says the firm repackaged and relabeled externally sourced semaglutide API without quality unit procedures, documentation, process or cleaning validation, or validated analytical methods, misstating manufacturer and dates; semaglutide and tirzepatide APIs were distributed to the U.S.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- CGMP deviations for APIs
- quality unit oversight and traceability failures
- drug listing and establishment registration failures (misbranding)
- failure to validate manufacturing processes
- inadequate cleaning validation
- inadequate analytical method validation
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Misbranding)
Recent warning letters with related regulatory findings:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.